Saturday Edition
Stay updated with Archyde – your source for breaking news, global headlines, economy, entertainment, health, technology, and sports. Fresh stories daily.
Recent developments in biopharma include Replimune’s third FDA approval attempt, a $10.5B Pfizer-China collaboration, and WHO-endorsed Ebola therapies. These updates reflect evolving strategies in cancer treatment, global drug development, and ... Read More
Continuous Coverage
The first time I saw a school resource officer (SRO) restrain a 12-year-old in a Texas middle school…
The recent high-profile investigation into the Kouri Richins case, featured on CBS’s 48 Hours, serves as a grim…
Northville Dentist Charged in Medicaid Fraud Scheme: Implications for Patient Trust and Healthcare Integrity A Northville dentist faces…
The New Bedford Light is officially calling for artist submissions for its upcoming “Arts Illuminated” live talk show…
A jaw-dropping tennis shot during Roland Garros 2026, captured on TikTok, has sparked global debate on technique and…
When a rare “blue moon” rises this weekend, it’s not just a celestial event—it’s a tech-driven phenomenon. Astronomical…
Global Affairs
Israel is quietly constructing a permanent military base in the eastern Mediterranean—near Cyprus’s exclusive economic zone (EEZ)—to project…
Markets And Money
Who: Dutch officials Bruno Bruins and Marion Koopmans face parliamentary scrutiny over coronavirus response. What: Inquiry into decision-making…
Digital Culture
Paralives, the ambitious life-simulation engine developed by indie studio Paralives Studio, successfully launched into Early Access on May…
Science And Wellbeing
Researchers have developed a next-generation tau positron emission tomography (PET) tracer that demonstrates superior sensitivity in detecting tau…
Screen And Sound
John Carney’s *Power Ballad* emerges as a standout in his filmography, blending musical storytelling with heartfelt drama, as…
Fixtures And Form
Luis Mendoza dissects Di Giannantonio’s Mugello P1 dominance and Acosta’s Q1 struggles, revealing tactical nuances and franchise implications…
